Difference between revisions of "Ephedra"
| Line 1: | Line 1: | ||
| − | A systematic review of 117 studies found that ephedra and ephedrine promoted modest shortter weight loss (approximately 0.9 kg/month more than with placebo) but increased the risk of psychiatric, autonomic, gastrointestinal, and cardiac complications by a factor of 2.2 to 3.6. <ref>Shekelle et al | + | A systematic review of 117 studies found that ephedra and ephedrine promoted modest shortter weight loss (approximately 0.9 kg/month more than with placebo) but increased the risk of psychiatric, autonomic, gastrointestinal, and cardiac complications by a factor of 2.2 to 3.6.<ref>Shekelle et al, [http://www.bmj.com/cgi/reprint/327/7418/E222?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=ephedra&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT Ephedra], JAMA March 26, 2003;289:1537-1545</ref>. |
An analysis of adverse reactions reported to poison control centers found that products containing ephedra accounted for 64% of all adverse reactions to herbs in the United States, yet these products represented only 0.82% of herbal product sales<ref>Bent et al, [http://www.bmj.com/cgi/reprint/327/7418/E222?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=ephedra&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT Ann Intern Med] March 18, 2003;138:468-471</ref> | An analysis of adverse reactions reported to poison control centers found that products containing ephedra accounted for 64% of all adverse reactions to herbs in the United States, yet these products represented only 0.82% of herbal product sales<ref>Bent et al, [http://www.bmj.com/cgi/reprint/327/7418/E222?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=ephedra&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT Ann Intern Med] March 18, 2003;138:468-471</ref> | ||
Revision as of 00:17, 29 January 2010
A systematic review of 117 studies found that ephedra and ephedrine promoted modest shortter weight loss (approximately 0.9 kg/month more than with placebo) but increased the risk of psychiatric, autonomic, gastrointestinal, and cardiac complications by a factor of 2.2 to 3.6.[1].
An analysis of adverse reactions reported to poison control centers found that products containing ephedra accounted for 64% of all adverse reactions to herbs in the United States, yet these products represented only 0.82% of herbal product sales[2]
Notes
- ↑ Shekelle et al, Ephedra, JAMA March 26, 2003;289:1537-1545
- ↑ Bent et al, Ann Intern Med March 18, 2003;138:468-471
